Comorbidity between major depressive disorder and physical diseases: a comprehensive review of epidemiology, mechanisms and management

World Psychiatry, Год журнала: 2023, Номер 22(3), С. 366 - 387

Опубликована: Сен. 15, 2023

Populations with common physical diseases – such as cardiovascular diseases, cancer and neurodegenerative disorders experience substantially higher rates of major depressive disorder (MDD) than the general population. On other hand, people living MDD have a greater risk for many diseases. This high level comorbidity is associated worse outcomes, reduced adherence to treatment, increased mortality, health care utilization costs. Comorbidity can also result in range clinical challenges, more complicated therapeutic alliance, issues pertaining adaptive behaviors, drug‐drug interactions adverse events induced by medications used mental disorders. Potential explanations prevalence above involve shared genetic biological pathways. These latter include inflammation, gut microbiome, mitochondrial function energy metabolism, hypothalamic‐pituitary‐adrenal axis dysregulation, brain structure function. Furthermore, several antecedents related social factors (e.g., socioeconomic status), lifestyle variables activity, diet, sleep), stressful live childhood trauma). Pharmacotherapies psychotherapies are effective treatments comorbid MDD, introduction interventions well collaborative models digital technologies provide promising strategies improving management. paper aims detailed overview epidemiology specific including bidirectional risk; pathways potentially implicated pathogenesis diseases; socio‐environmental that serve both protective factors; management prevention treatment. We conclude future directions emerging research optimal

Язык: Английский

---

Association between immune-inflammation-based prognostic index and depression: An exploratory cross-sectional analysis of NHANES data

Journal of Affective Disorders, Год журнала: 2024, Номер 362, С. 75 - 85

Опубликована: Июнь 27, 2024

Язык: Английский

---

Greater Symptom Burden and Poorer Quality of Life Outcomes Are Associated With The Co-Occurrence of Anxiety and Depression During Cancer Chemotherapy

Seminars in Oncology Nursing, Год журнала: 2025, Номер unknown, С. 151809 - 151809

Опубликована: Фев. 1, 2025

Anxiety and depression are common symptoms in oncology patients undergoing chemotherapy. Study purpose was to evaluate for differences severity of (ie, fatigue, energy, sleep disturbance, cognitive function, pain) quality life (QOL) outcomes among three subgroups outpatients with distinct joint anxiety profiles. Oncology (N = 1328) completed measures state depression, six times over two cycles Latent profile analysis done identify AND Patients trait anxiety, morning evening pain, as well generic disease-specific QOL at enrollment. Differences the classes symptom scores were evaluated using parametric non-parametric tests. Three profiles identified named: Low Depression (57.5%, Both Low), Moderate (33.7%, Moderate), High (8.8%, High). All showed a "dose-response effect" worsened, all increased). Likewise, both general (except spiritual well-being) measures, decreased worsened. Compared classes, other reported lower well-being domain. More than 40% receiving chemotherapy experience moderate high levels depression. These report an extremely burden significant decrements domains QOL. Clinicians need perform comprehensive assessments during In addition, referrals targeted interventions needed manage multiple improve patients'

Язык: Английский

---

Exploring of Antidepressant Components and Mechanisms of Zhizichi Decoction: Integration of Serum Pharmacochemistry, Network Pharmacology and Anti‐inflammatory Analysis Verification

Analytical Science Advances, Год журнала: 2025, Номер 6(1)

Опубликована: Фев. 21, 2025

ABSTRACT Using LC–MS to screen and analyse the characteristics of components biological systems is a new approach study pharmacological substance basis traditional Chinese medicine, which has strong novelty in analytical science. This analyses antidepressant material Zhizichi decoction through integration strategy serum pharmacochemistry, network pharmacology immunoreactivity verification, helps overcoming limitations TCM research provided perspective for studying ZZCD. First all, blood from SD rats was collected before after administration initially. The migration constituents were then analysed using ultra‐high performance liquid chromatography‐Q‐TOF‐MS/MS. By integrating TCMSP databases with pharmacochemistry results, we constructed ‘ingredients–targets–pathways’ protein–protein interaction decoction's depression‐relieving. Finally, inhibitory effects active ingredient groups comprised pharmacodynamic identified prior on IL‐1β, IL‐6 TNF‐α measured an inflammatory cytokines experiments. From study, 146 their attribution hypothesized characterized. They as 18 prototype 128 metabolites, 121 Phase I 7 II metabolites. illustrated relationships 20 definitive ingredients, 85 potential targets 21 signalling pathways connection depression. predicted by reported be associated neuroinflammation, suggested that further anti‐inflammatory experiment required. For effect AIGs 1 composed 14 basically equivalent whole ZZCD recipe, AIG critical inhibit factors defined components’ decoction, providing scientific foundation pursuit drugs depression treatments.

Язык: Английский

---

Anti-depression-like effect of Mogroside V is related to the inhibition of inflammatory and oxidative stress pathways

European Journal of Pharmacology, Год журнала: 2023, Номер 955, С. 175828 - 175828

Опубликована: Июнь 25, 2023

Язык: Английский

---

Astroglial Connexin 43-Mediated Gap Junctions and Hemichannels: Potential Antidepressant Mechanisms and the Link to Neuroinflammation

Cellular and Molecular Neurobiology, Год журнала: 2023, Номер 43(8), С. 4023 - 4040

Опубликована: Окт. 24, 2023

Язык: Английский

---

Microbiota–gut–brain axis: the mediator of exercise and brain health

Deleted Journal, Год журнала: 2024, Номер 4

Опубликована: Янв. 1, 2024

Abstract The brain controls the nerve system, allowing complex emotional and cognitive activities. microbiota–gut–brain axis is a bidirectional neural, hormonal, immune signaling pathway that could link gastrointestinal tract to brain. Over past few decades, gut microbiota has been demonstrated be an essential component of plays crucial role in regulating most functions various body organs. effects on occur through production neurotransmitters, hormones, metabolites, regulation host-produced or synthesis metabolites by themselves. This affects host's behavior, mood, attention state, brain's food reward system. Meanwhile, there intimate association between exercise. Exercise can change numerically qualitatively, which may partially responsible for widespread benefits regular physical activity human health. Functional magnetic resonance imaging (fMRI) non-invasive method show areas enabling delineation specific regions involved neurocognitive disorders. Through combining exercise tasks fMRI techniques, researchers observe higher functions. However, exercise's health via have little studied. article reviews highlights connections these three interactions, will help us further understand positive provide new strategies approaches prevention treatment diseases.

Язык: Английский

---

Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Concurrent Use of Crocin During Chemoradiation for Esophageal Squamous Cell Carcinoma

Cancer Investigation, Год журнала: 2024, Номер 42(2), С. 155 - 164

Опубликована: Фев. 7, 2024

Crocin is the major active carotenoid of saffron (Crocus sativus L.). Its pluripotent effects have led to a growing body literature investigating its antitumor properties as well diverse potentials for mood stabilization, normal tissue protection, and inflammation reduction; However, there gap in clinical trials testing this substance cancer patients. In randomized, double-blind, placebo-controlled trial, patients with newly diagnosed esophageal squamous cell carcinoma were randomly assigned either 30 mg/day crocin or placebo, prescribed during neoadjuvant chemo-radiotherapy. The primary endpoints pathological response toxicity, secondary depression anxiety levels survival analysis.

Язык: Английский

---

Meta-analysis on inflammation and autonomic nervous system of coronary heart disease combined with depression

BMJ Open, Год журнала: 2024, Номер 14(3), С. e079980 - e079980

Опубликована: Март 1, 2024

This meta-analysis aimed to explore the association between inflammatory factors, heart rate variability (HRV) and coexistence of coronary disease (CHD) depression. Systematic review meta-analysis. Complying with Meta-analysis Of Observational Studies in Epidemiology statement. We searched PubMed, Web Science EMBASE for data from inception date 16 March 2023. included cross-sectional cohort studies inclusion criteria: (1) patients CHD; (2) depression measurement (3) including factors or cardiac biomarkers HRV. Two authors databases independently. The effect estimates heterogeneity were synthesised by Review Manager V.5.3. Sensitivity analysis publication bias analysed STATA software. quantitative synthesis outcomes presented mean difference (MD) standard MD (SMD) 95% CI. By searching databases, we identified a total 6750 articles. There 22 articles left after selection, 6344 participants. indicated that CHD had higher levels C reaction protein (CRP) (SMD 0.50, CI (0.19 0.81), p=0.001), high-sensitivity reactive (hs-CRP) 0.28, (0.07 0.48), p=0.008), IL-6 0.49, (0.05 0.92), p=0.03) lower level RR interval SD all intervals -0.64, (-1.11 -0.17), 5 min averages normal (MD -12.77 ms, (-21.20 -4.33), p=0.003), overage each segment -13.83 (-15.94 -11.72), p<0.00001), root square successive differences (MD: -8.02 (-13.62 -2.43), p=0.005), proportion adjacent cycles differing >50 ms (pNN50) -0.86, (-1.41 -0.31), p=0.002), than those without study underscores elevated CRP, hs-CRP, HRV It emphasises importance clinicians assessing potentially identify depressive conditions.

Язык: Английский

---

Association and mechanism of montelukast on depression: A combination of clinical and network pharmacology study

Journal of Affective Disorders, Год журнала: 2024, Номер 360, С. 214 - 220

Опубликована: Май 31, 2024

Язык: Английский

---